★★

UTI

Extension of Put Option Date for Convertible Bonds Spreads Short-Term Liquidity Burden, Incurring 15% Annual Interest


  • UTI INC. filed a corrective disclosure extending the put option date for its 1st unregistered private convertible bond (KRW 54.15B, issued May 2024) from May 22, 2026 to June 1, 2026, with 15% annual compound interest on the extended period.
  • The extension, agreed by all bondholders, suggests the company aims to ease short-term cash pressure by spreading repayments. However, the high 15% interest cost will increase financial expenses.
  • The initial conversion price was KRW 36,559, with a floor of KRW 25,592 (70% of initial) due to market decline adjustments. The current stock price (KRW 21,850) is below the floor, making conversion unlikely. Bondholders are more likely to exercise the put option for principal repayment.
  • The company has a call option to buy back up to 30% (10% for certain holders) of the bonds, providing some control over dilution and ownership, but its exercise is conditional and uncertain.
  • Full conversion would add approximately 1.48 million shares (about 7.5% of current outstanding), posing a medium-term dilution risk. However, immediate dilution is unlikely given the current stock price.
  • [AI Summary]The put option extension reduces short-term liquidity pressure but incurs high interest costs, signaling potential credit stress. With the stock price below the conversion floor, bondholders are likely to demand repayment, amplifying cash flow risk. Investors should monitor the company's ability to meet its obligations.

KOSDAQ Filing Information


  • Filing: [Correction of Description] Report on Major Matters (Decision on Issuance of Convertible Bonds)
  • Company: UTI (179900)
  • Submission: UTI INC.
  • Receipt: 06-01-2026